Moberg Pharma AB (CHIX:MOBS) EPS (Basic): kr-0.55 (TTM As of Mar. 2026)


CHIX:MOBS Moberg Pharma AB CHIX:MOBS
59 GF Score
Price kr17.55
GF Value kr23.52
! 1 Warning Sign
View Full Analysis

What is Moberg Pharma AB EPS (Basic)?

Moberg Pharma AB CHIX:MOBS 59 EPS (Basic) is kr-0.55 as of Mar. 2026. GuruFocus rates CHIX:MOBS with a GF Score™ of 59/100 and a GF Value™ of kr23.52. The stock has 1 warning sign investors should review.

Moberg Pharma AB's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was kr-0.03. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was kr-0.55.

Moberg Pharma AB's EPS (Diluted) for the three months ended in Mar. 2026 was kr-0.03. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was kr-0.55.

Moberg Pharma AB's EPS without NRI for the three months ended in Mar. 2026 was kr-0.03. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -0.55.

During the past 3 years, the average EPS without NRI Growth Rate was -38.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was -25.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Moberg Pharma AB's highest 3-Year average EPS without NRI Growth Rate was 61.90% per year. The lowest was -52.80% per year. And the median was 10.05% per year.

Moberg Pharma AB  (CHIX:MOBs) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Moberg Pharma AB EPS (Basic) Related Terms

Moberg Pharma AB EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Moberg Pharma AB's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Moberg Pharma AB EPS (Basic) Chart

Moberg Pharma AB Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec21 Dec22 Dec23 Dec24
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.49 1.13 -1.38 -1.33 -6.74

Moberg Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.06 -0.16 -0.09 -0.27 -0.03
CHIX:MOBS
59GF Score
Moberg Pharma AB CHIX:MOBS
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Moberg Pharma AB EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Moberg Pharma AB's Basic EPS for the fiscal year that ended in Dec. 2024 is calculated as

Basic EPS (A: Dec. 2024 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-255.111-0)/37.848
=-6.74

Moberg Pharma AB's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-1.263-0)/46.693
=-0.03

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of kr-0.55 mean?
Moberg Pharma AB (CHIX:MOBS) has a EPS (Basic) of kr-0.55 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Moberg Pharma AB and its competitors.
Is Moberg Pharma AB's EPS (Basic) too high?
Moberg Pharma AB's current EPS (Basic) is kr-0.55. Overall, Moberg Pharma AB has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does Moberg Pharma AB's EPS (Basic) compare to ZTS?
Moberg Pharma AB's EPS (Basic) of kr-0.55 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Moberg Pharma AB and its competitors. Moberg Pharma AB's current EPS (Basic) is kr-0.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moberg Pharma AB stock overvalued right now?
Moberg Pharma AB (CHIX:MOBS) has a current EPS (Basic) of kr-0.55. The stock's GF Value™ is kr23.52, compared to a current price of kr17.55 — trading 25.4% below its estimated fair value. The current EPS (Basic) is kr-0.55. Moberg Pharma AB's overall GF Score™ is 59/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Moberg Pharma AB (CHIX:MOBS), the current EPS (Basic) is kr-0.55 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Moberg Pharma AB (CHIX:MOBS) Overvalued in 2026?

Based on GuruFocus' analysis, Moberg Pharma AB stock appears to be undervalued. The current stock price of kr17.55 is trading 25.4% below its estimated GF Value™ of kr23.52.

Key valuation signals for CHIX:MOBS:

  • EPS (Basic): kr-0.55
  • GF Value™: kr23.52 vs. price of kr17.55 (25.4% below fair value)
  • GF Score™: 59/100 with 1 warning sign

No single metric tells the full story. See the CHIX:MOBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Moberg Pharma AB Business Description

Other Exchanges MBGPF:USAMOB:Sweden
Address Gustavslundsvagen 42, 5th Floor, Bromma, Stockholm, SWE, SE-167 51
Moberg Pharma AB is a Swedish pharmaceutical company which develops and commercializes proprietary pharmaceuticals based on proven substances. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.
59GF Score

Get the complete analysis for CHIX:MOBS

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr17.55
Price
kr23.52
GF Value